Vasopharm Overview

  • Founded
  • 1998
Founded
  • Status
  • Private
  • Employees
  • 11
Employees
  • Latest Deal Type
  • 2ndary - Private
  • Investors
  • 9

Vasopharm General Information

Description

Developer of novel therapeutics designed to offer treatment of cerebrovascular diseases. The company's therapeutics develops small molecule medicinal products which modulate the bioavailability of biological diseases, enabling healthcare professional to combat cerebral and cardiovascular diseases with advanced technology.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Other Industries
Pharmaceuticals
Drug Discovery
Primary Office
  • Friedrich-Bergius-Ring 15
  • 97076 Wuerzburg
  • Germany
+49 0931 0000000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Vasopharm Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
11. Secondary Transaction - Private 000.00 Completed Clinical Trials - Phase 3
10. Later Stage VC 11-Jul-2019 000.00 000.00 Completed Clinical Trials - Phase 3
9. Secondary Transaction - Private 000.00 Completed Clinical Trials - Phase 3
8. Later Stage VC (Series G) 21-Jan-2016 000.00 000.00 000.00 Completed Clinical Trials - Phase 3
7. Later Stage VC (Series F) 24-Jun-2013 00.000 000.00 000.00 Completed Clinical Trials - Phase 1
6. Later Stage VC (Series D) 04-May-2009 00.000 000.00 000.00 Completed Clinical Trials - Phase 1
5. Secondary Transaction - Private 09-Jun-2008 000.00 Completed Clinical Trials - Phase 1
4. Later Stage VC (Series B) 30-Jan-2006 000.00 000.00 000.00 Completed Startup
3. Later Stage VC 15-Dec-2004 $5.62M Completed Startup
2. Grant 11-Feb-2004 $5.62M Completed Startup
To view Vasopharm’s complete valuation and funding history, request access »

Vasopharm Executive Team (9)

Name Title Board Seat Contact Info
Christian Wandersee Chief Executive Officer & Co-Founder
Frank Tegtmeier Ph.D Chief Scientific Officer & Managing Director
Ulrich Walter MD Co-Founder
Peter Scheurer Ph.D Head of CMC & Deputy Quality Manager
Reinhard Schinzel Ph.D Head of Research & Drug Safety Operations
You’re viewing 5 of 9 executive team members. Get the full list »

Vasopharm Board Members (7)

Name Representing Role Since
Andrew Clark Ph.D Vasopharm Chairman & Supervisory Board Member 000 0000
Christian Leikert Self Board Member 000 0000
Christopher Townsend Vasopharm Board Member 000 0000
Clemens Doppler Ph.D HeidelbergCapital Board Member 000 0000
Klaas de Boer Entrepreneurs Fund Board Member 000 0000
You’re viewing 5 of 7 board members. Get the full list »

Vasopharm Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Vasopharm Investors (9)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Creathor Venture Venture Capital Minority 000 0000 000000 0
EF Investments Other Minority 000 0000 000000 0
Ringtons Limited Other Minority 000 0000 000000 0
Fort Rock Capital Venture Capital Minority 000 0000 000000 0
HeidelbergCapital PE/Buyout Minority 000 0000 000000 0
You’re viewing 5 of 9 investors. Get the full list »